Ocugen Plans Live Webcast to Discuss Financial Results
MALVERN, Pa. — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology innovator focused on gene therapies for causes of blindness, is preparing to host an informative webcast. This live event is set for 8:30 a.m. ET where the company will share key insights from its third quarter financials and updates about their ongoing projects.
What to Expect from the Upcoming Call
During this expectedly engaging conference call, Ocugen will dive into its recent financial performance and provide strategic updates on its business initiatives. Participants will find the webcast informative, as it aims to elucidate the company’s position in the competitive landscape of gene therapy.
Event Details
For those interested in attending the live session, they should note the following details:
- Dial-in Numbers: Domestic callers can reach the line at (800) 715-9871, while international attendees can connect through (646) 307-1963.
- Conference ID: 3029428.
- Webcast Access: The event can be found on the Ocugen investor site, where you can engage with the discussion live.
Post-Webcast Availability
If you miss the live call, fret not! A replay will be made available for roughly 45 days, allowing interested parties to catch up with the discussion at their convenience. This is a great opportunity for those who may not be available to join live.
Ocugen's Pioneering Gene Therapy Approach
Ocugen is recognized for its innovative approach in addressing conditions leading to blindness. Utilizing a modifier gene therapy platform, the company targets complex diseases rooted in multiple genetic imbalances as opposed to traditional gene therapies that focus on single gene deficiencies.
Their advances in gene-agnostic therapies are poised to tackle significant medical unfulfilled needs for patients affected by various inherited retinal diseases, such as retinitis pigmentosa and geographic atrophy, resulting in vision loss for millions.
Engage with Ocugen for More Updates
For individuals eager to keep up with Ocugen, their website and social media platforms are treasure troves of information. You can find a wealth of knowledge about their groundbreaking therapies, company news, and future prospects.
Contacting Ocugen
If you have any inquiries or need further information, please reach out to:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
Frequently Asked Questions
What is the purpose of Ocugen's upcoming webcast?
The webcast will cover the company's third-quarter financial results and provide updates on ongoing business strategies and gene therapy projects.
How can I participate in Ocugen's conference call?
Interested participants can dial the provided numbers or join through the webcast link on Ocugen's investor site during the scheduled time.
Will a recording of the webcast be available afterward?
Yes, the company will offer a replay of the call for about 45 days after the event for those who cannot attend live.
What advancements does Ocugen focus on?
Ocugen develops gene therapies that aim to address complex diseases leading to blindness, leveraging a modifier gene therapy platform capable of affecting multiple gene networks.
Who can be contacted for more information regarding Ocugen?
For additional inquiries, Tiffany Hamilton, AVP and Head of Communications, can be contacted via email at Tiffany.Hamilton@ocugen.com.
